Current News & Updates

Recursion Has Opened 13 Sites for REC-994 Trial

February 15, 2023 –Recursion Pharmaceuticals has twelve US sites enrolling cavernous malformation patients in Phase 2 of their REC-994 Sycamore trial. This is the first industry-sponsored trial of a medicine for cerebral cavernous malformations, a massive milestone toward better treatments. The most recent site to open is Emory University in Atlanta.  Please visit our website’s…

Watch the first documentary about Cavernous Malformation

Eloquent” is our first-ever documentary about patients and families dealing with the ups and downs of a cavernous malformation diagnosis. Their stories will both pull at your heartstrings and inspire you! Also, hear from our experts, who deliver a hopeful message to anyone on this challenging journey. Watch award-winning and film festival winner, Eloquent.